Olivia's Feed
Jun 23, 2015

Exclusive: Charterhouse eyes possible $1.1 billion sale of UK medical company Tunstall

LONDON/NEW YORK (Reuters) – British private equity firm Charterhouse [CHCAP.UL] is working with JP Morgan (JPM.N: Quote, Profile, Research, Stock Buzz) on options for healthcare company Tunstall, in a deal which could value the company at up to 700 million pounds ($1.1 billion), a source familiar with the matter said on Tuesday.

Tunstall provides care services and assisted living for elderly and disabled people at home, with devices like alerting systems and monitoring technology.

Jun 23, 2015

Charterhouse eyes possible $1.1 bln sale of UK medical company Tunstall – source

LONDON/NEW YORK, June 23 (Reuters) – British private equity
firm Charterhouse is working with JP Morgan
on options for healthcare company Tunstall, in a deal which
could value the company at up to 700 million pounds ($1.1
billion), a source familiar with the matter said on Tuesday.

Tunstall provides care services and assisted living for
elderly and disabled people at home, with devices like alerting
systems and monitoring technology.

Jun 23, 2015

Exclusive: Plus-sized retailer FullBeauty seeks sale or IPO

By Olivia Oran and Greg Roumeliotis

(Reuters) – FullBeauty Brands Inc is exploring a sale or an initial public offering that could value the privately held plus-sized women’s and men’s fashion retailer at more than $1.5 billion, including debt, according to people familiar with the matter.

The New York-based company, owned since February 2013 by private equity firms Charlesbank Capital Partners and Webster Capital, is working with investment bank JPMorgan Chase & Co (JPM.N: Quote, Profile, Research, Stock Buzz) on the potential sale, the people said this week.

Jun 17, 2015

Goldman to summer interns: Don’t stay in the office overnight

NEW YORK (Reuters) – Goldman Sachs Group Inc has told its summer investment banking interns not to stay in the office overnight in a bid to improve working conditions for its junior staff.

The move, according to company sources and confirmed by a Goldman spokesman, illustrates how Wall Street banks are seeking to curb excessive hours worked by young employees who see internships and entry-level jobs as a chance for a lucrative investment banking career.

Jun 10, 2015

Teva switches legal counsel after Mylan challenge

By Olivia Oran

(Reuters) – Teva Pharmaceutical Industries Ltd (TEVA.TA: Quote, Profile, Research, Stock Buzz) has changed the law firm it had tapped for advice on its $40 billion attempt to take over smaller rival Mylan NV (MYL.O: Quote, Profile, Research, Stock Buzz) after a court sided with the latter’s bid to seek a preliminary injunction against the previous law firm.

Teva is now working with Sullivan & Cromwell LLP as legal counsel in its proposal to acquire Mylan, the Israeli drugmaker said late on Monday. It was previously working with another law firm, Kirkland & Ellis LLP.

Jun 8, 2015

Pozen to redomicile as it agrees to buy Tribute Pharmaceuticals

June 8 (Reuters) – Specialty pharmaceuticals company Pozen
Inc said on Monday it would acquire Tribute
Pharmaceuticals Canada Inc for about $144 million, in a
deal that would shift its domicile to Ireland and cut its tax
bill.

The merged company, to be called Aralez Pharmaceuticals Plc,
will focus on cardiovascular treatments and be led by Adrian
Adams, who previously served as chief executive of men’s
healthcare-focused company Auxilium Pharmaceuticals. Auxilium
was acquired by Endo International Plc for $2.6 billion
last year.

Jun 5, 2015

Teva raises its stake in acquisition target Mylan

By Olivia Oran

(Reuters) – Teva Pharmaceutical Industries Ltd (TEVA.TA: Quote, Profile, Research, Stock Buzz) has increased its stake in Mylan NV (MYL.O: Quote, Profile, Research, Stock Buzz) to nearly 2.2 percent as it presses on with an unsolicited bid for its generic drug-making rival, a regulatory filing showed on Friday.

The strategy is another sign of Teva’s commitment to its $40 billion takeover proposal for Mylan, as the latter continues to pursue its own hostile bid for over-the-counter drug company Perrigo Company PLC (PRGO.N: Quote, Profile, Research, Stock Buzz).

Jun 2, 2015

Exclusive: Teva poised to raise its stake in Mylan – sources

By Olivia Oran

(Reuters) – Teva Pharmaceutical Industries Ltd (TEVA.TA: Quote, Profile, Research, Stock Buzz) is looking to buy more shares in Mylan NV (MYL.O: Quote, Profile, Research, Stock Buzz), positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid, people familiar with the matter said.

The strategy is a sign of Teva’s commitment to its $40 billion bid for Mylan, as the latter presses on with its own $34 billion hostile bid for over-the-counter drug company Perrigo Company Plc (PRGO.N: Quote, Profile, Research, Stock Buzz).

Jun 2, 2015

Teva poised to raise its stake in Mylan -sources

By Olivia Oran

(Reuters) – Teva Pharmaceutical Industries Ltd is
looking to buy more shares in Mylan NV, positioning
itself for a possible legal challenge to the generics drugmaker
that has spurned its takeover bid, people familiar with the
matter said.

The strategy is a sign of Teva’s commitment to its $40
billion bid for Mylan, as the latter presses on with its own $34
billion hostile bid for over-the-counter drug company Perrigo
Company Plc.

May 29, 2015

Health insurer Humana explores sale – source

May 29 (Reuters) – Humana Inc is considering selling
itself after receiving multiple expressions of takeover
interest, a person familiar with the matter said on Friday,
highlighting the potential for further consolidation in the U.S.
health insurance industry.

Humana is working with investment bank Goldman Sachs Group
Inc on the potential sale, the person said, asking not to
be identified because the matter is confidential.